Literature DB >> 26980457

Multiple cranial neuropathies following zoledronic acid infusion: a relationship? Clinical features and pathogenic discussion concerning a case.

S Deshayes1, N Martin Silva1, J Cogez2, A Baldolli1, S Fedrizzi3, B Bienvenu1, A Aouba4.   

Abstract

The widespread use of bisphosphonates, especially in osteoporosis, has led to a greater number of reports of side effects. We describe for the first time a case of a 75-year-old female patient with a history of indolent sicca syndrome who developed multiple cranial neuropathies after zoledronic acid infusion. In this case, the elimination of the main causes of multiple cranial neuropathies, the chronology with zoledronic acid infusion, the absence of secondary complications of the Sjögren's syndrome, reported cases of similar peripheral nerve injuries with interferon infusions, the spontaneous remission of this multiple cranial neuropathy in parallel with the induced flu-like syndrome, argue for its iatrogenic origin, probably by a great release of inflammatory mediators in this particular background of primary Sjögren's syndrome.

Entities:  

Keywords:  Bisphosphonates; Iatrogenic nerve toxicity; Multiple cranial neuropathies; Sjögren’s syndrome; Zoledronic acid

Mesh:

Substances:

Year:  2016        PMID: 26980457     DOI: 10.1007/s00198-016-3567-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  21 in total

Review 1.  Endocrine and neurological adverse effects of the therapeutic interferons.

Authors:  T Vial; G Choquet-Kastylevsky; C Liautard; J Descotes
Journal:  Toxicology       Date:  2000-01-17       Impact factor: 4.221

2.  A 35-year history of recurrent multiple cranial neuropathy due to primary Sjögren's syndrome.

Authors:  E Touzé; P Blanche; M Zuber
Journal:  J Neurol       Date:  1999-10       Impact factor: 4.849

3.  A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss.

Authors:  D Santini; B Vincenzi; M Caraglia; G Tonini
Journal:  Ann Oncol       Date:  2006-10-04       Impact factor: 32.976

4.  Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.

Authors:  Athanasios D Anastasilakis; Stergios A Polyzos; Polyzois Makras; Grigorios T Sakellariou; Ilias Bisbinas; Athina Gkiomisi; Sideris Delaroudis; Spyridon Gerou; Iris Ballaouri; Dimitrios Oikonomou; Socrates E Papapoulos
Journal:  Bone       Date:  2012-02-15       Impact factor: 4.398

5.  The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy.

Authors:  Keiko Mori; Masahiro Iijima; Haruki Koike; Naoki Hattori; Fumiaki Tanaka; Hirohisa Watanabe; Masahisa Katsuno; Asako Fujita; Ikuko Aiba; Akihiko Ogata; Toyokazu Saito; Kunihiko Asakura; Mari Yoshida; Masaaki Hirayama; Gen Sobue
Journal:  Brain       Date:  2005-07-27       Impact factor: 13.501

Review 6.  Safety issues with bisphosphonate therapy for osteoporosis.

Authors:  Ernest Suresh; Michael Pazianas; Bo Abrahamsen
Journal:  Rheumatology (Oxford)       Date:  2013-07-09       Impact factor: 7.580

7.  [Clinical case of the month. Bilateral optic neuropathy secondary to biphosphonate therapy].

Authors:  S Lespagnard; S Bonnet; P Betz
Journal:  Rev Med Liege       Date:  2010 Jul-Aug

8.  An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.

Authors:  D Thiébaud; A Sauty; P Burckhardt; P Leuenberger; L Sitzler; J R Green; A Kandra; J Zieschang; P Ibarra de Palacios
Journal:  Calcif Tissue Int       Date:  1997-11       Impact factor: 4.333

Review 9.  Central and peripheral neurological complications of primary Sjögren's syndrome.

Authors:  Anne-Laure Fauchais; Laurent Magy; Elisabeth Vidal
Journal:  Presse Med       Date:  2012-07-26       Impact factor: 1.228

10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; E V McCloskey; H Johansson; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-10-19       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.